1. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives

   • Ronaldo A. Ribeiro
   • Carlos W. S. Wanderley
   • Roberto C. P. Lima-Júnior

   Review Article 02 September 2016 Pages: 881 - 893

   

2. Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas

   • Michael J. Nathenson
   • Edward Sausville

   Review Article 20 May 2016 Pages: 895 - 919

3. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors

   • John Sarantopoulos
   • Sanjay Goel
   • Sunil Sharma

   Original Article 28 September 2016 Pages: 921 - 927

   

4. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment

   • Kevin R. Kelly
   • Nashat Gabrail
   • A. Craig Lockhart

   Original Article 16 September 2016 Pages: 929 - 939

   

5. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience

   • Naohiro Oda
   • Katsuyuki Hotta
   • Katsuyuki Kiura

   Original Article 02 September 2016 Pages: 941 - 947

   

6. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer

   • Boram Han
   • Joo Young Jung
   • Dae Young Zang

   Original Article 15 September 2016 Pages: 949 - 958

   

7. Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

   • Martin J. Edelman
   • Rena Lapidus
   • Jogarao Gobbru

   Original Article 12 September 2016 Pages: 959 - 967

   

8. Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

   • Martin J. Edelman
   • Rena Lapidus
   • Jogarao Gobburu

   Erratum 27 September 2016 Pages: 969 - 969

9. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo

   • Cong Wang
   • Ran Wang
   • Hongmin Liu

   Original Article 12 September 2016 Pages: 971 - 982

   

10. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia

    • Stine Nygaard Nielsen
    • Kathrine Grell
    • Kjeld Schmiegelow

    Original Article 06 September 2016 Pages: 983 - 994

    

11. Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors

    • Yosuke Tamura
    • Hiroshi Nokihara
    • Tomohide Tamura

    Original Article 15 September 2016 Pages: 995 - 1002

    

12. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study

    • Wijith Munasinghe
    • Sven Stodtmann
    • Hao Xiong

    Original Article Open access 05 October 2016 Pages: 1003 - 1011

    

13. Population pharmacokinetic–pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer

    • Masato Fukae
    • Yoshimasa Shiraishi
    • Ichiro Ieiri

    Original Article 05 October 2016 Pages: 1013 - 1023

    

14. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells

    • Xu Wang
    • Bo Yang
    • Baojing Ma

    Original Article 29 September 2016 Pages: 1025 - 1031

    

15. Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats

    • Alexandre Iarkov
    • Doreen Appunn
    • Valentina Echeverria

    Original Article 05 October 2016 Pages: 1033 - 1039

    

16. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma

    • Soushi Ibata
    • Tsutomu Sato
    • Junji Kato

    Original Article Open access 13 October 2016 Pages: 1041 - 1049

    

17. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia

    • Savitha Varatharajan
    • John C. Panetta
    • Poonkuzhali Balasubramanian

    Original Article 13 October 2016 Pages: 1051 - 1058

    

18. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors

    • Hanna Bailey
    • Jordan P. McPherson
    • Neeraj Agarwal

    Original Article 15 October 2016 Pages: 1059 - 1071

    

19. Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma

    • Saeed Zavareh
    • Milad Mahdi
    • Hamid Hashemi-Moghaddam

    Original Article 17 October 2016 Pages: 1073 - 1084

    

20. Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma

    • Jong-Ho Kim
    • In-Gu Do
    • On Behalf of the KBSMC Pancreatobiliary Cancer Team

    Original Article 15 October 2016 Pages: 1085 - 1092

    

21. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients

    • Victoria J. Forster
    • Frederik W. van Delft
    • Christina Halsey

    Short Communication Open access 22 September 2016 Pages: 1093 - 1096

    

22. Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?

    • Nuggehally R. Srinivas

    Letter to the Editor 13 May 2016 Pages: 1097 - 1098

23. 15-0600-Dr. Fox’s response to letter to the editor

    • Elizabeth Fox
    • Frank M. Balis

    Letter to the Editor 11 October 2016 Pages: 1099 - 1100